Polatuzumab vedotin binds CD79b on B cells, is internalized, and releases MMAE, which then binds beta‑tubulin (vinca domain) to inhibit microtubule polymerization, causing G2/M arrest and apoptosis. Beta‑tubulin is not the directly targeted antigen; killing occurs only after ADC delivery via CD79b.